Exclusives

Rion announced initiation of Phase 2A clinical study to assess the safety and efficacy of its Purified Exosome Product (PEP) for management of DFUs. A positive outcome of the pivotal study will be followed by the submission of a Biologics...

3M noted that the Health Care spin remains on track for the first half of 2024, subject to customary closing conditions. Also, 3M named Chris Barry EVP and group president of its Medical Solutions Division, effective March 1, 2024. Barry...

Recce Pharma announced its Phase I/II clinical trial assessing the safety and efficacy of RECCE 327 (R327), a broad-spectrum anti-infective, given as a topical treatment for DFIs, met all primary endpoints of resolving/curing bacterial...

Swift Medical announced $8.0MM of new financing co-led by existing investors. Swift plans enhancements to its platform in 2024 including enhanced data security, improved interoperability, and enhanced device capabilities.

MolecuLight Corp announced that the MolecuLight i:X and DX devices have been awarded a federal supply contract by the US Department of Veterans Affairs.

A 4.3 million-patient database review examined the effect of social determinants of health on DFU rates. Overall, 144,564 individuals with diabetes were seen over 4 years, 8,351 developed a DFU or 5.8%. Of those with DFUs, infection occurred...